This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): allopurinol
Description: Allopurinol is a structural isomer of the natural purine hypoxanthine. It inhibits xanthine oxidase, an enzyme involved in the metabolism of hypoxanthine to xanthine, with the production of uric acid. Uric acid crystals are responsible for gout. Inhibition of the enzyme also leads to higher levels of certain purines that exert a negative feedback on purine biosynthesis.
Deal Structure: Allopurinol is marketed by Prometheus Labs in the United States, while in other countries it continues to be marketed by GlaxoSmithKline.
In May 2011, Prometheus Laboratories announced that it has entered into a definitive agreement to be acquired by Nestl Health Science S.A., a wholly-owned subsidiary of Nestl S.A., for an undisclosed amount. Financial terms were not disclosed. The acquisition was completed in July 2011.
Partners: GlaxoSmithKline plc
Pink Sheet In Brief: Glaxo Wellcome Zyloprim
Pink Sheet Nabi
Pink Sheet Warner-Lambert’s Nipent (pentostatin)
Additional information available to subscribers only: